If companies had nine lives, Astal Laboratories Ltd (BSE: 512600, ₹83.8, Market Cap ₹90.2 crore) would be on its third — and this one finally seems interesting. Born in 1993 as Macro International Ltd peddling saddles and bridles from Kanpur, it almost died before resurrecting itself as a pharma-intermediates manufacturer. The latest quarter (Q2 FY26) saw revenue jump 185% YoY to ₹37.52 crore, while PAT climbed 29% to ₹2.58 crore. That’s like going from selling horse rugs to making molecules for Swiss labs — quite literally.
Despite a modest promoter holding of 18.2%, and no dividends (because clearly cash is for chemistry), the company boasts ROE of 30.1% and ROCE of 34.8% — metrics that would make even seasoned pharma peers nod. With a P/E of 9.12x, Astal looks like that undervalued backbencher who suddenly starts topping the class.
So how did this ex-departmental store morph into a real estate side hustle and then into a potential pharma upstart with Swiss export orders? Buckle up, because this ride from Kanpur’s saddlery to Switzerland’s REACH-certified labs is both bizarre and beautiful.
2. Introduction
Imagine you ran a shop in Kanpur selling bridles and leather reins. Fast forward 30 years, and your company’s issuing REACH certificates for exporting Piroctone Olamine to Switzerland. That’s not a startup pivot; that’s reincarnation with a PhD in chemistry.
Once upon a time, Macro International Ltd was busy managing departmental stores and saddlery exports. When that business tanked, it parked itself into real estate, perhaps building the labs it would later need. Then in 2022, Aceso Research Labs LLP swooped in like a white-coated knight, picking up a 26% stake at just ₹10 per share through an open offer. By 2023, the company rebranded itself as Astal Laboratories Ltd, signalling a full pivot into the pharmaceutical and specialty chemicals sector.
Now, with revenue crossing ₹100 crore in FY25 (from basically zero in FY21), Astal’s story is pure corporate rebirth. It’s like if Raymond suddenly started making vaccines — confusing but profitable.
Their Swiss connection? In November 2025, Astal bagged a Letter of Intent (LOI) from a Swiss client for 60 tonnes of Piroctone Olamine, to be delivered from Dec 2025 to Jun 2026. For context, this compound is used in anti-dandruff shampoos and skincare — so yes, the company has literally gone from polishing leather to polishing scalps.
Not bad for a firm that couldn’t pay its rent a decade ago.
3. Business Model – WTF Do They Even Do?
Astal Laboratories now focuses on manufacturing pharmaceutical intermediates and specialty chemicals, positioning itself in a sector that feeds giants like Sun Pharma, Cipla, and Dr. Reddy’s Labs.
The company’s bread and butter (or bromine and butanol?) lies in producing advanced intermediates that act as raw materials for finished drug formulations. This includes compounds like Piroctone Olamine and other niche APIs that are exported to regulated markets.
In October 2025, Astal acquired Sriven Pharmachem, a Hyderabad-based pharma intermediates firm, via a 1:1 share swap valued at ₹277.17 crore. That’s serious muscle-flexing for a ₹90 crore market cap entity — imagine a Maruti acquiring a Mercedes dealership.
With this acquisition, Astal is expanding its manufacturing base, diversifying product lines, and gaining access to EU markets (thanks to its shiny new REACH certificate). It’s a calculated chemical leap.
The company also shows early signs of integration: it’s absorbing Sriven’s R&D capacity, likely to develop patented intermediates for global clients. The big question? Can this former Kanpur trader handle the complexity of European compliance and pharma-scale production without tripping over its own balance sheet?
4. Financials Overview
Let’s bring out the calculator and goggles.
Quarterly Comparison (₹ crore)
Metric
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
37.52
13.16
25.33
185.1%
48.1%
EBITDA
3.87
2.89
3.15
34.0%
22.8%
PAT
2.58
2.00
2.09
29.0%
23.4%
EPS (₹)
2.40
2.03
2.13
18.2%
12.7%
Commentary: Astal’s Q2 FY26 results look like chemistry done right — exothermic and value-creating. Revenue’s up nearly 3x YoY, profit growth is strong, and the operating margin holds near 10%. Sure, this isn’t Dr. Reddy’s scale yet, but for a microcap that had zero revenue two years ago, it’s basically a metamorphosis.
If you’re wondering about sustainability, remember: the Swiss LOI means export visibility till mid-2026. That’s like having your next six quarters pre-sold.
5. Valuation Discussion – Fair Value Range Only
Let’s run the holy trinity of valuations.
a) P/E Method: EPS (TTM) = ₹9.84 Industry P/E = 31x Current P/E = 9.12x
Lower bound: 12x × ₹9.84 = ₹118
Upper bound: 20x × ₹9.84 = ₹197
b) EV/EBITDA Method: EV = ₹98 crore EBITDA (TTM) = ₹15 crore EV/EBITDA = 6.66x Peer average = 15–20x Fair value range = ₹120–₹190
c) Simplified DCF (5 years, 15% discount, 20% growth) Approximate range = ₹110–₹160 per share
➡ Fair Value Range (Educational Estimate): ₹110–₹190 per share
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
The last 12 months have been an all-you-can-eat buffet of boardroom updates.
Dec 2023: Macro International officially rebranded as Astal Laboratories Ltd. Goodbye saddles, hello solvents.
Jul 2024: Announced fund-raising via 57 lakh convertible warrants — because dilution is the new R&D.
